Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1729257 | 0.90 | F2R (0.37) | F2RKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL6544708 | 0.89 | F2R (0.47) | F2RKDM4EMAPTRAB9ANPC1 | |
| Bromide SCHEMBL1729005 | 0.89 | F2R (0.48) | F2RKDM4EMAPTRAB9ANPC1 | |
| Bromide SCHEMBL5490771 | 0.83 | F2R (0.39) | F2RKDM4EMAPTRAB9ANPC1 | |
| Bromide SCHEMBL1729969 | 0.82 | F2R (0.36) | F2RKDM4EMAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL1729337 | 0.81 | F2R (0.47) | F2RKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL1732107 | 0.81 | F2R (0.46) | F2RKDM4EMAPTRAB9ANPC1 | |
| Bromide SCHEMBL5484009 | 0.81 | F2R (0.48) | F2RKDM4EMAPTRAB9ANPC1 | |
| Bromide SCHEMBL1732250 | 0.81 | F2R (0.36) | F2R | |
| SCHEMBL14449168 | 0.81 | F2R (0.45) | F2RKDM4EMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065676-A1 | COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH NAR AGONISTS | SCHERING CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065676-A1 | COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH NAR AGONISTS | F2R, F2RL1, F2RL3 | F2R 1/4885KDM4E 4337/4885MAPT 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.